Compare Stocks → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:MBIONASDAQ:OASMNASDAQ:OBSV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsMBIOMustang Bio$0.24-22.6%$0.58$0.22▼$8.17$2.49M1.75705,773 shs46.33 million shsOASMOasmia Pharmaceutical AB (publ)$0.05$1.46$0.94▼$5.70$3.74M0.9698,414 shsN/AOBSVObsEva$0.01$0.08▼$2.14$7.94M0.688.94 million shs2.78 million shs5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%+27.66%MBIOMustang Bio-7.49%+14.73%-9.25%-75.20%-92.79%OASMOasmia Pharmaceutical AB (publ)0.00%0.00%+149.50%+149.50%-0.20%OBSVObsEva0.00%0.00%0.00%-96.97%-97.62%WARNING about the death of the U.S. dollar… (Ad)Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!)Get Colonial Metals' new Precious Metals Investment Guide.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/AMBIOMustang Bio2.5062 of 5 stars3.55.00.00.02.40.00.6OASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/AMBIOMustang Bio3.00Buy$11.504,691.67% UpsideOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/ACurrent Analyst RatingsLatest MBIO, OASM, OBSV, and CYAD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2024MBIOMustang BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$25.00 ➝ $2.00(Data available from 5/22/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00MBIOMustang BioN/AN/AN/AN/A($0.48) per shareN/AOASMOasmia Pharmaceutical AB (publ)$220K17.00N/AN/A$0.63 per share0.08OBSVObsEva$20.11M0.00N/AN/A$0.41 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/AMBIOMustang Bio-$51.60M-$4.40N/AN/AN/AN/A-1,243.22%-195.64%8/12/2024 (Estimated)OASMOasmia Pharmaceutical AB (publ)-$18.95MN/A0.00∞N/A-8,633.64%-43.94%-28.92%N/AOBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ALatest MBIO, OASM, OBSV, and CYAD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AOASMOasmia Pharmaceutical AB (publ)N/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad OncologyN/AN/AN/AMBIOMustang BioN/A0.530.53OASMOasmia Pharmaceutical AB (publ)N/A0.800.73OBSVObsEvaN/A0.610.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/AMBIOMustang Bio9.95%OASMOasmia Pharmaceutical AB (publ)0.11%OBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%MBIOMustang Bio2.10%OASMOasmia Pharmaceutical AB (publ)N/AOBSVObsEva14.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableOASMOasmia Pharmaceutical AB (publ)5774.97 millionN/ANot OptionableOBSVObsEva4877.97 million66.74 millionNot OptionableMBIO, OASM, OBSV, and CYAD HeadlinesRecent News About These CompaniesMay 22 at 3:16 AM | americanbankingnews.comObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.comMay 22 at 3:16 AM | americanbankingnews.comObsEva (NASDAQ:OBSV) Coverage Initiated by Analysts at StockNews.comMay 14, 2024 | americanbankingnews.comObsEva (NASDAQ:OBSV) Coverage Initiated at StockNews.comApril 3, 2024 | globenewswire.comObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinMarch 19, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsFebruary 28, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 26, 2024 | benzinga.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesNovember 11, 2023 | morningstar.comObsEva SA OBSNNovember 11, 2023 | morningstar.comObsEva SA OBSEFJune 18, 2023 | fool.comObsEva (NASDAQ: OBSV)May 10, 2023 | news.google.comTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserverMay 2, 2023 | news.google.comObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo FinanceMay 2, 2023 | news.google.comObsEva Says Fabien De Ladonchamps Is New CEO - NasdaqMay 2, 2023 | news.google.comObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswireApril 28, 2023 | news.google.comGameto Appoints Teri Loxam as Chief Financial Officer - citybizApril 28, 2023 | news.google.comObsEva Annual Report 2022 - Marketscreener.comApril 28, 2023 | news.google.comObsEva Annual Report 2022 - Yahoo FinanceApril 28, 2023 | news.google.comObsEva Annual Report 2022 - BenzingaApril 28, 2023 | news.google.comObsEva Annual Report 2022 - EIN NewsApril 28, 2023 | news.google.comGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR NewswireNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Oasmia Pharmaceutical AB (publ)NASDAQ:OASMOasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.ObsEvaNASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.